Date | Price Target | Rating | Analyst |
---|---|---|---|
7/29/2024 | $41.00 | Overweight → Equal Weight | Barclays |
3/11/2024 | Buy → Hold | Societe Generale | |
2/6/2024 | $77.00 → $54.00 | Buy → Neutral | Redburn Atlantic |
1/3/2024 | $68.00 → $60.00 | Buy → Neutral | BofA Securities |
11/15/2023 | $68.00 → $55.00 | Overweight → Neutral | Cantor Fitzgerald |
11/9/2023 | $55.00 | Hold | Deutsche Bank |
11/2/2023 | $68.00 → $54.00 | Outperform → Neutral | Daiwa Securities |
10/27/2023 | $55.00 → $53.00 | Reduce → Hold | HSBC Securities |
For Immediate Release: June 14, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA issued a proposed exemption for certain cottage cheese products from the requirements of the Food Traceability Rule. The proposal would exempt Grade “A” cottage cheese that appears on the Interstate Milk Shippers List from the requirements of the r
For Immediate Release: March 08, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA announced proposed new regulations to provide animal drug sponsors with predictable requirements for the labeling of prescription and over-the-counter new animal drugs, as well as new animal drugs for use in animal feeds. The proposed content and
For Immediate Release: November 17, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, to mark the 15th anniversary of the FDA foreign offices, the FDA published an interview with Susan Winckler, who was FDA chief of staff when the first office was opened in Beijing on November 19, 2008. Winckler is now CEO of the Reagan-Udall Foundation
Bristol Myers Squibb (NYSE:BMY) will announce results for the third quarter of 2024 on Thursday, October 31, 2024. Company executives will review financial results and address inquiries from investors and analysts during a conference call beginning at 8:00 a.m. ET on the same date. Investors and the general public are invited to listen to a live webcast of the call at http://investor.bms.com. Investors and the public can register for the live conference call here. Those unable to register can access the live conference call by dialing in the U.S. toll free 1-833-816-1116 or international +1 412-317-0705. Materials related to the call will be available at http://investor.bms.com prior to th
Bristol Myers Squibb (NYSE:BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty cents ($0.60) per share on the $0.10 par value common stock of the company. The dividend is payable on November 1, 2024, to stockholders of record at the close of business on October 4, 2024. In addition, the Board of Directors has declared a quarterly dividend of fifty cents ($0.50) per share on the company's $2.00 convertible preferred stock, payable on December 2, 2024, to stockholders of record at the close of business on November 5, 2024. About Bristol Myers Squibb Company Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, devel
Data from proof-of-concept, randomized, Phase 2 RELATIVITY-104 trial exploring the combination of nivolumab, relatlimab (1:1) and chemotherapy as first-line treatment for stage IV or recurrent NSCLC; BMS initiating Phase 3 RELATIVITY-1093 trial Ten-year follow-up data from CheckMate -067 showed continued durable, long-term survival benefit of Opdivo® (nivolumab) plus Yervoy® (ipilimumab) in patients with advanced or metastatic melanoma Results from several early-phase clinical trials reinforce the strength and diversity of BMS' oncology portfolio, including novel combinations and modalities, across a wide range of solid tumors Bristol Myers Squibb (NYSE:BMY) today announced the presentat
4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)
4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)
4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)
Bristol Myers Squibb (NYSE:BMY) today announced that its Board of Directors has elected independent director Michael R. McMullen to the Board, effective July 1, 2024. Mr. McMullen will serve as a member of the Audit Committee of the Board of Directors. "We are pleased to welcome Mr. Michael McMullen to our Board of Directors," said Christopher Boerner, Ph.D., board chair and chief executive officer, Bristol Myers Squibb. "Mike's extensive experience in managing large businesses and global operations, combined with his proven track record of delivering excellent shareholder returns, will prove valuable as we continue to strengthen the company's long-term growth profile, progress our pipeli
Tapestry, Inc. (NYSE:TPR), a house of iconic accessories and lifestyle brands consisting of Coach, Kate Spade, and Stuart Weitzman, today announced that Kevin Hourican, President and Chief Executive Officer of Sysco Corporation (NYSE:SYY), and David Elkins, Executive Vice President and Chief Financial Officer of Bristol Myers Squibb (NYSE:BMY), have been appointed to the Company's Board of Directors. The appointments of Mr. Hourican and Mr. Elkins to the Board bring the membership to eleven, including ten independent directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240229220934/en/Kevin Hourican (Photo: Business Wire) J
Boerner begins as CEO November 1 Giovanni Caforio to Retire as Chair After 23 Years at the Company Bristol Myers Squibb (NYSE:BMY) announced that its Board of Directors has unanimously elected Christopher Boerner, Ph.D., to serve as Chair of the Board, effective April 1, 2024. He succeeds Giovanni Caforio, M.D., who will step down as Chair of the Board on April 1, 2024 and retire from the company after 23 years of service. Boerner was named Executive Vice President, Chief Operating Officer and CEO-elect on April 26 and, as of November 1, Boerner will be Chief Executive Officer of Bristol Myers Squibb. "I am honored to become CEO and later Board Chair," said Boerner. "Giovanni has st
Final results from the DAYBREAK long-term extension study showed brain volume loss decreased during Phase 3 studies and was sustained with continuous Zeposia treatment for up to 5 years More than eight years of DAYBREAK data confirm established safety profile of Zeposia, with rates of treatment-emergent adverse events declining or stable over time Bristol Myers Squibb (NYSE:BMY) today announced new data from the Phase 3 DAYBREAK trial demonstrating that decreased rates of brain volume loss were sustained in the open-label extension (OLE) for patients treated with Zeposia (ozanimod) for relapsing forms of multiple sclerosis. These findings showed that patients receiving continuous Zeposia
TCER® IMA401 is a novel, next-generation, half-life extended bispecific T cell engager directed against an HLA-A*02-presented peptide derived from MAGEA4 and MAGEA8 with high target copy numbers on various solid cancersData from the first-in-human Phase 1 dose escalation trial demonstrate initial anti-tumor activity and a manageable tolerability profile for TCER® IMA401 monotherapy; patient population includes 35 heavily pre-treated patients across 16 different solid tumor types; dose escalation is ongoingObjective response rate (ORR) 29%, confirmed ORR (cORR) 25%, disease control rate (DCR) of 53% and tumor shrinkage rate of 53% in the efficacy population treated with relevant IMA401 doses
These data represent the longest reported median overall survival from a Phase 3 advanced melanoma trial; data selected for official ESMO press conference At ten years, more than 40% (43%) of patients treated with Opdivo plus Yervoy were alive; a decade ago, this patient population faced a survival rate of around 25% after only one year Data to be presented today as a mini oral and simultaneously published in The New England Journal of Medicine Bristol Myers Squibb (NYSE:BMY) today announced 10-year follow-up data from CheckMate -067, a randomized, double-blind, Phase 3 clinical trial, which showed continued durable improvement in survival with first-line Opdivo® (nivolumab) plus Yervoy®
4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)
4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)
3/A - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)
10-Q - BRISTOL MYERS SQUIBB CO (0000014272) (Filer)
8-K - BRISTOL MYERS SQUIBB CO (0000014272) (Filer)
11-K - BRISTOL MYERS SQUIBB CO (0000014272) (Filer)
Guggenheim Partners initiated coverage on Alumis Inc. (NASDAQ:ALMS), a clinical-stage biopharmaceutical company developing oral therapies for immune-mediated diseases. The investment thesis centers around a positive view of its lead asset ESK-001, a next-gen TYK2 inhibitor currently in development for plaque psoriasis and systemic lupus erythematosus (SLE). The company’s management expects to initiate a Phase 3 trial for plaque psoriasis in the second half of 2024, and data from the SLE study are expected in 2026. The analyst writes that favorable safety (with no risk of JAK class black box warning) and potential BIC efficacy make ESK-001 a potentially competitive alternative to ava
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Goldman Sachs cut the price target for SunPower Corporation (NASDAQ:SPWR) from $2 to $0.5. Goldman Sachs analyst Brian Lee maintained a Sell rating. SunPower shares gained 5.4% to close at $0.7158 on Monday. See how other analysts view this stock. Piper Sandler increased the price target for Cathay General Bancorp (NASDAQ:CATY) from $32 to $36. Piper Sandler analyst Matthew Clark maintained an Underweight rating. Cathay General Bancorp shares gained 2.4% to close at $43.02 on Monday. See how other
Deutsche Bank analyst James Shin maintains Bristol-Myers Squibb (NYSE:BMY) with a Hold and lowers the price target from $53 to $45.
Barclays downgraded Bristol-Myers from Overweight to Equal Weight and set a new price target of $41.00
Societe Generale downgraded Bristol-Myers from Buy to Hold
Redburn Atlantic downgraded Bristol-Myers from Buy to Neutral and set a new price target of $54.00 from $77.00 previously
SC 13G/A - BRISTOL MYERS SQUIBB CO (0000014272) (Subject)
SC 13G/A - BRISTOL MYERS SQUIBB CO (0000014272) (Subject)
SC 13G/A - BRISTOL MYERS SQUIBB CO (0000014272) (Subject)